PRLD
Prelude Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$4.87
+6.56%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.16
- Revenue estimate
- $27.7M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.20
- Revenue actual
- $5.7M
- Revenue estimate
- $5.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -115.1%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $10
- PT range
- $8.00 – $12
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.20 | -$0.14 | Beat 28.81% | $5.7M |
| May 12, 2026 | -$0.27 | -$0.13 | Beat 51.85% | $4.6M |
| Mar 10, 2026 | -$0.03 | -$0.20 | Miss -566.67% | $5.6M |
| Nov 12, 2025 | -$0.35 | -$0.26 | Beat 25.71% | $6.5M |
| Aug 14, 2025 | -$0.45 | -$0.41 | Beat 8.89% | — |
| Mar 10, 2025 | -$0.49 | -$0.38 | Beat 22.45% | $4.0M |
| Feb 15, 2024 | -$0.50 | -$0.47 | Beat 6.00% | $3.4M |
| Nov 1, 2023 | -$0.58 | -$0.45 | Beat 22.41% | — |
| Aug 3, 2023 | -$0.65 | -$0.54 | Beat 16.92% | — |
| Mar 15, 2023 | -$0.63 | -$0.60 | Beat 4.76% | — |
| Nov 14, 2022 | -$0.63 | -$0.63 | In line | — |
| Mar 16, 2022 | -$0.69 | -$0.71 | Miss -2.90% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026